Coratus Genetics, which is developing possible treatments for severe cardiovascular disease, has raised $9.85 million through a private stock placement.
Coratus (Amex: CAQ) sold the stock at $5.22 a share, and half of the money has closed.
Coratus has an upcoming PhaseIIb clinical trial for its drug. When the first patient is treated, the second round will close, the
company said.
The buyers also received warrants for an additional 235,869 shares.
